ArticleActa pharmacologica Sinica2020
Antiepileptic geissoschizine methyl ether is an inhibitor of multiple neuronal channels.
Article in Acta pharmacologica Sinica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Lvguidingan inhibits Nav1.2 and epilepsy-associated SCN2A gain-of-function variants.Acta pharmacologica Sinica · 2026Article
- Ion-Channel Activity of Characteristic Alkaloids From Uncaria rhynchophylla.Chemistry & biodiversity · 2026Article
- Evidence and Tradition in Dialogue: Biological Sex Variability in Phytomedicine Research as a Foundation for Safety, Efficacy, and Robust Evidence Standards.Medicines (Basel, Switzerland) · 2026Review
- Exploration of Canarium odontophyllum fruit phytoconstituents as potential candidates against epilepsy using in silico studies.Journal, genetic engineering & biotechnology · 2025Article
- Call for Standardizing Uncaria rhynchophylla as the Sole Origin of Uncariae Ramulus cum Uncis.Phytochemical analysis : PCA · 2025Article
- Article
- Trace component fishing strategy based on offline two-dimensional liquid chromatography combined with PRDX3-surface plasmon resonance forJournal of pharmaceutical analysis · 2025Article
- Harnessing the power of natural alkaloids: the emergent role in epilepsy therapy.Frontiers in pharmacology · 2024Review
- Comparative transcriptome analysis between inbred lines and hybrids provides molecular insights into KFrontiers in plant science · 2022Article
- Protection against HTranslational neuroscience · 2022Article
- Identification of a Subtype-Selective Allosteric Inhibitor of GluN1/GluN3 NMDA Receptors.Frontiers in pharmacology · 2022Article
- Network Pharmacology and Molecular Docking to Explore the Mechanism of Kangxian Decoction for Epilepsy.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Geissoschizine methyl ether (GM) is an indole alkaloid isolated from Uncaria rhynchophyll (UR) that has been used for the treatment of epilepsy in traditional Chinese medicine. An early study in a glutamate-induced mouse seizure model demonstrated that GM was one of the active ingredients of UR. In this study, electrophysiological technique was used to explore the mechanism underlying the antiepileptic activity of GM. We first showed that GM (1-30 μmol/L) dose-dependently suppressed the spontaneous firing and prolonged the action potential duration in cultured mouse and rat hippocampal neurons. Given the pivotal roles of ion channels in regulating neuronal excitability, we then examined the effects of GM on both voltage-gated and ligand-gated channels in rat hippocampal neurons. We found that GM is an inhibitor of multiple neuronal channels: GM potently inhibited the voltage-gated sodium (Na
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.